Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.
about
Altering the tropism of lentiviral vectors through pseudotyping.Lentiviral vectors in gene therapy: their current status and future potentialGenetic engineering of T cells for adoptive immunotherapyGene transfer in humans using a conditionally replicating lentiviral vectorHIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors.Nanomaterial-Enabled Neural Stimulation.Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy.Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cellsEfficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory proteinEnhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin.Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology.Replication-competent lentivirus analysis of clinical grade vector products.Effects of targeted suppression of glutaryl-CoA dehydrogenase by lentivirus-mediated shRNA and excessive intake of lysine on apoptosis in rat striatal neurons.Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation.Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines.Transgenic sheep generated by lentiviral vectors: safety and integration analysis of surrogates and their offspring.Lentivirus as a potent and mechanistically distinct vector for genetic immunizationThe state of the art of adeno-associated virus-based vectors in gene therapy.A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs.RNA-interference-based gene therapy approaches to HIV type-1 treatment: tackling the hurdles from bench to bedside.Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).Recent advances in lentiviral vector development and applications.Gene therapy to the kidney using viral vectorsOcular gene delivery using lentiviral vectors.Personalized gene therapy locks out HIV, paving the way to control virus without antiretroviral drugs.Viral vectors encoding endomorphins and serine histogranin attenuate neuropathic pain symptoms after spinal cord injury in rats.Knockdown of zinc finger protein, X-linked (ZFX) inhibits cell proliferation and induces apoptosis in human laryngeal squamous cell carcinoma.Suppression of lung cancer metastasis-related protein 1 (LCMR1) inhibits the growth of colorectal cancer cells.RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells.Lentivirus-mediated inhibition of Med19 suppresses growth of breast cancer cells in vitro.Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion.SHARP-2 gene silencing by lentiviral-based short hairpin RNA interference prolonged rat kidney transplant recipients' survival time.Inhibition of hepatocelluar carcinoma MAT2A and MAT2beta gene expressions by single and dual small interfering RNALentivirus mediated shRNA interference targeting MAT2B induces growth-inhibition and apoptosis in hepatocelluar carcinoma.Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy.Optimizing transfection of primary human umbilical vein endothelial cells using commercially available chemical transfection reagents.SMC1A knockdown induces growth suppression of human lung adenocarcinoma cells through G1/S cell cycle phase arrest and apoptosis pathways in vitro.
P2860
Q24538987-08CEFC49-7A51-42B6-AA13-A0B8CFB87628Q24629462-9A3C9DC5-B228-4214-965C-B5BDB3CF2D23Q24642718-955F7168-AC79-47DD-A787-1B1FA7A1A92FQ24675343-B419B415-CB4D-4EA4-B21C-811F0FF949C7Q24816355-FCB2C4D5-4EDA-4865-A1EB-39DC3D767D24Q26751221-D45DCB73-93BD-4577-A0AF-7DAAD0584D42Q33397933-B2D4214A-A4D6-44E0-894A-2005C26AAC61Q33788055-18BFEC79-AAFB-433E-91BE-DFC20ECDA53DQ33926275-31C33D8F-B5C5-4D6F-84F1-4423B77B523BQ34273081-B1131A76-D648-4269-BACE-0DA20A652C83Q34484917-2F49452B-0B5E-4F1A-B965-1B1BC578489AQ34485522-05EE2EA9-132C-455A-A81E-A297DE6D6051Q34621742-885A6CC9-B171-4618-B6F0-E57B70109C9AQ34712933-2815A952-694C-4FB0-99A7-F48D4F2F81F3Q35001971-940FDF07-6AA1-4C0C-A731-E0F266224E3EQ35878632-241AC029-F2CE-4976-AA73-C0B96B39D83BQ36200146-AF01394A-4492-49FE-AF9E-6423F000C334Q36414343-BD2CA237-BD4E-4576-8CAC-49FA3DD18079Q36710283-72EE0066-9F40-44D2-B282-49D1DB22A5C3Q36969195-1C92BE53-C2F1-4F7D-8986-ED0CB9BD7CC9Q36972714-65D8B2FC-FF24-42F9-BC14-5354F41D1730Q37331638-6B2A3201-FCAC-481A-9AD1-096CCDA2592CQ37566034-311B2A92-5CC0-496F-9ADD-85FD43E8BAA9Q37615161-6A57843A-073E-4DDF-8D66-F41D562BB9BCQ37678176-1EFF71E6-BE3C-4E0B-9CD7-4F96F38543EFQ37786559-50FE30A8-93B2-4A0D-823E-BA5BC4175B15Q37952564-0BC3CE5D-20FF-4DC7-B45E-7ECDDE09698EQ38462651-060878D6-DE39-4ED5-9E72-54C2443BD9FFQ38922658-96E3EE38-C2F1-4548-B1FA-CB77B1FAAAE5Q39456234-823A5065-3D37-48E8-971F-9C2942FCD5ACQ39512233-B458C13C-0B02-4D11-B3F6-A6D21465F5DBQ39616040-AF351DF6-D5DC-429C-B0E4-A23304E309B8Q39648495-26135AFF-7024-4FDE-99CE-839274D41EDDQ39813577-CA08039D-97B5-4A1E-96F5-763F72E7D615Q39827069-B1B8CA4B-12FE-4599-ACD5-27093D42E3F0Q39913607-70D0E749-54F1-46A0-8BE0-EE54868116A0Q39951184-5569C6B8-F4D1-4033-B197-36DAD471C41AQ40183063-D56166EB-D2BD-4907-877A-E359BF75600CQ41008486-142E59C0-F24A-4AD0-B501-6CC05DEAF021Q41876194-AED467B1-19E2-4A12-A323-A0963BEB70D2
P2860
Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Regulatory considerations for ...... st clinical lentiviral vector.
@ast
Regulatory considerations for ...... st clinical lentiviral vector.
@en
type
label
Regulatory considerations for ...... st clinical lentiviral vector.
@ast
Regulatory considerations for ...... st clinical lentiviral vector.
@en
prefLabel
Regulatory considerations for ...... st clinical lentiviral vector.
@ast
Regulatory considerations for ...... st clinical lentiviral vector.
@en
P2093
P356
P1433
P1476
Regulatory considerations for ...... st clinical lentiviral vector.
@en
P2093
Boro Dropulic
Bruce L Levine
Carl H June
Cathleen Afable
Gwendolyn K Binder
Kathy Schonely
Laurent M Humeau
Peter Manilla
Rob-Roy MacGregor
Tessio Rebello
P356
10.1089/HUM.2005.16.17
P577
2005-01-01T00:00:00Z